Show simple item record

dc.contributor.authorDemirci, Selami
dc.contributor.authorDoğan, Ayşegül
dc.contributor.authorTürkmen Bacak, Neşe
dc.contributor.authorTelci, Dilek
dc.contributor.authorÇağlayan, Ahmet Burak
dc.contributor.authorBeker, Mustafa Çağlar
dc.contributor.authorKılıç, Ertuğrul
dc.contributor.authorÖzkan, Ferda
dc.contributor.authorDede, Bülent
dc.contributor.authorŞahin, Fikrettin
dc.date.accessioned10.07.201910:49:13
dc.date.accessioned2019-07-10T19:35:41Z
dc.date.available10.07.201910:49:14
dc.date.available2019-07-10T19:35:41Z
dc.date.issued2017en_US
dc.identifier.citationDemirci, S., Doğan, A., Türkmen Bacak, N., Telci, D., Çağlayan, A. B., Beker, M. Ç. ... Şahin, F. (2017) Poloxamer P85 increases anticancer activity of schiff base against prostate cancer in vitro and in vivo. Anti-Cancer Drugs, 28(8), 869-879. https://dx.doi.org/10.1097/CAD.0000000000000528en_US
dc.identifier.issn0959-4973
dc.identifier.issn1473-5741
dc.identifier.urihttps://hdl.handle.net/20.500.12511/901
dc.identifier.urihttps://dx.doi.org/10.1097/CAD.0000000000000528
dc.description.abstractProstate cancer is the second most common cancer among men and the leading cause of death after lung cancer. Development of hormone-refractory disease is a crucial step for prostate cancer progression for which an effective treatment option is currently unavailable. Therefore, there is a need for new agents that can efficiently target cancer cells, decrease tumor growth, and thereby extend the survival of patients in late-stage castration-resistant prostate cancer. In the current study, a novel heterodinuclear copper(II)Mn(II) Schiff base complex combined with P85 was used to evaluate anticancer activity against prostate cancer in vitro and in vivo. Cell proliferation and cytotoxicity were evaluated by cell viability, gene, and protein expression assays in vitro. Results showed that the heterodinuclear copper(II)Mn(II) complex-P85 combination decreased cell proliferation by upregulating the apoptotic gene expressions and blocking the cell proliferation-related pathways. Tramp-C1-injected C57/B16 mice were used to mimic a prostate cancer model. Treatment combination of Schiff base complex and P85 significantly enhanced the cellular uptake of chemicals (by blocking the drug transporters and increased life time), suppressed tumor growth, and decreased tumor volume steadily over the course of the experiments. Overall, heterodinuclear copper(II)Mn(II) complex-P85 showed remarkable anticancer activity against prostate cancer in in vitro and in vivo.en_US
dc.language.isoengen_US
dc.publisherLippincott Williams and Wilkinsen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectCastration-Resistant Prostate Canceren_US
dc.subjectP85en_US
dc.subjectPoloxameren_US
dc.subjectProstate Canceren_US
dc.subjectSchiff Baseen_US
dc.titlePoloxamer P85 increases anticancer activity of schiff base against prostate cancer in vitro and in vivoen_US
dc.typearticleen_US
dc.relation.journalAnti-Cancer Drugsen_US
dc.departmentİstanbul Medipol Üniversitesi, Tıp Fakültesi, Temel Tıp Bilimleri Bölümü, Fizyoloji Ana Bilim Dalıen_US
dc.authorid0000-0002-6242-3709en_US
dc.authorid0000-0002-9476-8488en_US
dc.authorid0000-0001-6494-8923en_US
dc.identifier.volume28en_US
dc.identifier.issue8en_US
dc.identifier.startpage869en_US
dc.identifier.endpage879en_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.identifier.doi10.1097/CAD.0000000000000528en_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record